


16
MAR
2023



FLUICELL MAKES IN VITRO DEVELOPMENT PROGRESS IN TYPE 1 DIABETES THERAPEUTICS PROGRAM



Fluicell's R&D team is demonstrating important progress in the Company's type 1 diabetes therapeutics in vitro development and is now able to bioprint up to 200 islet-like insulin-producing microtissues in one experimental run. The amount corresponds to the number of transplanted islets that has been demonstrated in scientific literature to have a beneficial effect in vivo in mice. The progress constitutes a crucial step towards obtaining candidates for in vivo testing, planned to commence in 2024.

The islet-like microtissues are intended for use in the Company's planned in vivo experiments and are of comparable size to native pancreatic islets. Moreover, the islet-like microtissues, which are bioprinted directly on transplantable material, produce insulin in response to glucose stimulation at adequate levels.

CSO Tatsiana Lobovkina comments

We are now creating an amount of islet-like microtissues that corresponds to what is reported in studies on diabetes reversal in mice. We are already hitting many of our development targets that we have for this year, and we are excited about our progress. Right now, we are in advanced discussions on how to initiate in vivo testing and look forward to taking the project to the next step.

About Fluicell's therapeutic and in vitro model development

Fluicell is conducting development of advanced therapy medicinal products (ATMP) and human tissue-based disease models for drug development. Within the disease area type 1 diabetes, Fluicell is conducting therapeutic development based on insulin-producing islet-like microtissues. Fluicell's development activities are based on the high precision bioprinting platform **Biopixlar** and its ability to generate functional tissues with high precision.

« Fluicell at TERMIS-EU in Manchester



EXPERTISE

We are a pioneer in open-volume microfluidics for life science. Our team of specialists are able to support you to get the most of our products.



CUSTOMER SERVICE

Our professional team are ready to assist you. We speak English, Swedish, Chinese, French, Russian and Polish. We are dedicated to respond within 24h.



LEGAL AND SALES
CUSTOMER SUPPORT

Fluicell's compliance with GDPR



Flöjelbergsgatan 8C
SE - 431 37 Mölndal, Sweden

+46 762 08 33 54
info@fluicell.com

Corporate ID: 556889-3282
VAT: SE556889328201